We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Eden Research Plc | EDEN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.75 | 3.75 | 3.75 | 3.75 | 3.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 04/2/2025 02:12 by neutralpov supersonico 3 Feb '25 - 18:11 - 19859> What Bio stimulant is Eden's Syngenta Linkman working on and with what global Partner? Humair Tariq Eden research. Bio-Controls I Bio-Stimulants | Agriculture | Global Commercial | Sales & Marketing ...... -------------------- subsonico is, aside from being a loony conspiracy-obsessed fruitcake, a shameless CON-ARTIST! I went to the article linked to and did a SEARCH for EDEN Search Results: 0 matches End of. But the con-artist relies on the lazy and retreaded (e.g., Timbo Kitty) not clicking or reading or comprehending or being capable of comprehending, but instead was somehow supportive of the preposterous suggestion that this stock is investable.... Even "ROTFLMAOOOOO!!!!" seems inadequate. :D |
Posted at 30/1/2025 08:42 by supersonico supersonico - 03 Dec 2019 - 15:33:50 - 7197 of 19826 Eden Research - EDENInvesting, you say 'I very much doubt others will co-ordinate all that you suggest'. Who are the 'others' you mention? If I was not under strict self imposed NDAs myself I could quite easily quote references to further substantiate my assertions regarding a shared formulation issue. I have been the most consistent and accurate of this position for easily two years now and despite comfort updates from Eden my theory on parallel delays remains intact. |
Posted at 28/1/2025 18:38 by supersonico NUMBER OF AIM SECURITIES IN ISSUEAs of 28 January 2025, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 21 December 2024, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,608,629 10.61% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 44,756,732 8.39% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,201,307 5.66% Atul Unadkat 23,486,291 4.40% Unicorn Asset Management 23,076,923 4.33% J M Finn 22,381,562 4.20% Rathbones 21,567,400 4.04% Amati Global Investors 16,744,070 3.14% As of 28 January 2025, the directors' shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital A Abrey 2,314,732 0.43% S Smith 1,913,117 0.36% L van der Broek 1,621,808 0.30% R Cridland 745,552 0.14% D McAllan 323,017 0.11% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 June 2024, the number of shares in issue was 533,352,523. As of 21 June 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 56,037,526 10.51% Gresham House Asset Management Limited 52,882,786 9.92% Interactive Investor 41,915,712 7.86% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,964,424 4.31% JM Finn Nominees Limited 19,955,562 3.74% Amati Global Investors 16,744,070 3.14% Name Number of shares % of the issued ordinary share capital A Abrey 1,774,192 0.33% L van der Broek 1,621,808 0.30% S Smith 1,192,577 0.22% R Cridland 745,552 0.14% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 3 January 2024, the number of shares in issue was 533,352,523. SIGNIFICANT SHAREHOLDERS As of 3 January 2024 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 53,364,313 10.01% Gresham House Asset Management Limited 52,882,786 9.92% Octopus Investments 41,551,047 7.79% Sipcam Oxon S.p.A. 39,285,138 7.37% Interactive Investor 33,363,457 6.26% Canaccord Genuity Wealth Management 30,276,307 5.68% Unicorn Asset Management 23,076,923 4.33% Rathbones 23,040,287 4.32% Atul Unadkat 22,099,924 4.14% JM Finn Nominees Limited 20,147,562 3.78% Amati Global Investors 16,744,070 3.14% BGF Investment Management Limited 16,000,576 3.00% .................... As of 20 July 2023, the number of shares in issue was 381,108,607. SIGNIFICANT SHAREHOLDERS As of 20 July 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital Hargreaves Lansdown 45,307,219 11.89% Sipcam Oxon S.p.A. 37,614,830 9.87% Interactive Investor 31,957,945 8.39% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% BGF Investment Management Limited 20,233,000 5.31% JM Finn Nominees Limited 19,635,562 5.15% Atul Unadkat 18,811,765 4.94% Rathbone Nominees Limited 13,661,661 3.58% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% HSDL Stockbrokers 12,436,733 3.26% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% ................... NUMBER OF AIM SECURITIES IN ISSUE As of 21 March 2023, the number of shares in issue was 380,858,607. SIGNIFICANT SHAREHOLDERS As of 21 March 2023 significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 51,733,000 13.58% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 31,737,596 8.33% Gresham House Asset Management Limited 27,845,445 7.31% Interactive Investor 25,172,555 6.61% Canaccord Genuity Group Inc 22,584,000 5.93% JM Finn Nominees Limited 19,839,762 5.21% Atul Unadkat 18,117,567 4.76% Rathbone Nominees Limited 15,621,872 4.10% HSBC Global Custody Nominee (UK) Limited 13,066,384 3.43% Name Number of shares % of the issued ordinary share capital A Abrey 1,620,346 0.43% L van der Broek 929,500 0.24% S Smith 911,039 0.24% R Cridland 130,167 0.03% SHARES NOT IN PUBLIC HANDS In the terms of AIM Rules published July 2016 and insofar as it is aware, at 21 March 2023, 31.71% of the Company's AIM securities was not in public hands. .................... Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 03 Dec 2022 - 07:03:11 - 13502 of 14935 Eden Research - EDEN Atul keeps buying. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% supersonico - 05 Oct 2022 - 08:52:18 - 13219 of 14935 Eden Research - EDEN Selling yes..but it's a dribble which has been bought by Atul etal. As of 30 September 2022, the number of shares in issue was 380,858,607. As of 30 September 2022, significant shareholdings in the share capital of Eden Research plc were: Number of shares % of the issued ordinary share capital BGF Investment Management Limited 53,733,000 14.11% Sipcam Oxon S.p.A. 37,614,830 9.88% Hargreaves Lansdown 29,839,285 7.83% Gresham House Asset Management Limited 27,845,445 7.31% Canaccord Genuity Group Inc 22,584,000 5.93% Interactive Investor 20,027,730 5.26% JM Finn Nominees Limited 19,277,362 5.06% Atul Unadkat 17,545,098 4.61% Rathbone Nominees Limited 15,708,999 4.12% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.48% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 09 March 2022, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 09 March 2022, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Atul Unadkat 17,350,145 4.38% Rathbone Nominees Limited 16,095,276 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% .................... NUMBER OF AIM SECURITIES IN ISSUE As of 18 August 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 18 August 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 54,933,000 14.44% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,331,396 6.66% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,386,275 5.36% Interactive Investor 19,790,573 5.20% Rathbone Nominees Limited 16,122,338 4.24% Amati AIM VCT plc 14,282,652 3.76% HSBC Global Custody Nominee (UK) Limited 13,270,588 3.49% ................... Home SECURITIES INFORMATION NUMBER OF AIM SECURITIES IN ISSUE As of 21 February 2021, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 February 2021, significant shareholdings in the share capital of Eden Research plc were: Name Number of shares % of the issued ordinary share capital BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Gresham House Asset Management Limited 27,845,445 7.32% Hargreaves Lansdown 25,452,709 6.69% Canaccord Genuity Group Inc 22,584,000 5.94% JM Finn Nominees Limited 20,421,575 5.37% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,156,166 4.25% Interactive Investor 15,405,978 4.05% HSBC Global Custody Nominee (UK) Limited 14,015,588 3.69% NUMBER OF AIM SECURITIES IN ISSUE As of 21 August 2020, the number of shares in issue was 380,340,229. SIGNIFICANT SHAREHOLDERS As of 21 August 2020, significant shareholdings in the share capital of Eden Research plc were: BGF Investment Management Limited 58,333,000 15.34% Sipcam Oxon S.p.A. 37,614,830 9.89% Hargreaves Lansdown 30,276,493 7.96% Gresham House Asset Management Limited 27,845,445 7.32% Canaccord Genuity Group Inc 22,684,000 5.94% JM Finn Nominees Limited 21,774,435 5.72% Amati AIM VCT plc 16,937,750 4.45% Rathbone Nominees Limited 16,246,373 4.27% HSBC Global Custody Nominee (UK) Limited 14,007,734 3.68% Interactive Investor 12,992,073 3.42% 1 |
Posted at 21/1/2025 22:47 by kittybiscuits Thanks Investing. I have seen these numbers and heard the share price targets from the mgt team. I absolutely see the potential here, and agree powdery and Downey mildew, Ecovelex and insecticide are all likely to substantially improve Edens fortunes over time. Hopefully the USA will also start to show some meaningful progress. All of this is undoubtedly coming…For me, the question remains over how much ‘time’ for all of this to materialise. It’s is still taking too much time and thereforethe worry becomes short term funding. I have every confidence it will get there.. but cavindish have put a forecast of 20p on Eden for at least 2 years, and we are no where close. Sean and Alex’s predictions of far higher, although exciting, is nothing more than pipe dreams until we all start to see meaningful growth in the share price (I understand, as I’m sure you do why the share price is hanging around at current levels). Again, not trying to be a nay sayer or negative. Just realistic. Multiple years of revenue and sales growing YoY and the new products will only accelerate that… but when…. And more importantly when will be see consistent and meaningful share price growth. Then and only then, will enthusiasm for Eden be maintained. |
Posted at 21/1/2025 13:01 by investingisatrickygame KittyBiscuitsIf you look at the following presentation you will see Eden's current and future product sales forecast. Eden states this is *Based on peak sales and a full label of all key target diseases and crops Fair enough, but these forecasts far exceed anything Cavendish has published. How much attention are investors paying to this presentation? Does it need to be spoken to an audience so that it sinks in? From the presentation CURRENT (€M) Mevalone 2.8 Cedroz 8.2 inc US Ecovelex 3.6 to which you can hopefully, shortly, add another 14.4 with Downy Mildew and the insecticide If you add up the current and future opportunity, I believe you get to a figure of around €130+ million You have to assume we are pretty well advanced with Mevalone and Cedroz and their label extensions and regulatory approvals, accepting there is always more to come The Company has said EU wide approval of Ecovelex will come this year The Company has said Downy Mildew France, will come this year. That just leaves the insecticide and whether the Company has submitted regulatory papers in the EU and the US. This we do not know. Might we be waiting for this prior to appointing a commercial partner(s). Who knows. These numbers far exceed the current turnover of £4.3 million and perhaps it would be helpful to talk to a wide audience about this value opportunity, in laymans terms, such that the value proposition is understood by everyone. Currently, Cavendish says Eden's target price is 20p. This is purely based on a 1 year forecast of regulatory approved products and anticipated sales, is it not? The Company has said on film that in their opinion, managements opinions, the shares are already worth more than this. Allowing for the published product sales on the Interims, available for all to see, conditional on regulatory approvals and label extensions, what is managements view of what the share price would look like, would be fairly valued at, in the event of this sales outcome. Values are published, so it is not unreasonable for them to paint the same picture for the share price, after all, they have already commented on the same. Some inspiration and belief for investors is perhaps one of the things needed to get the share price moving. Of course, removing a big seller (BGF) and a nice DM France regulatory approval would help and enhance this messaging. |
Posted at 04/1/2025 12:03 by kittybiscuits I get and understand the Eden process, but the timelines still are a dark art for me! Over the years I have learnt to at least double what Eden suggests. (For clarity not necessarily to obtain the approval is double, but before any notable impact on the business is double).As much as I’d love to see 20p or more this year, I think in a years time I’d just be satisfied we’re at or near 10p and posting a small profit. Hopefully, by end of year Exolelex will have been approved by regulators across the EU and beyond in some territories. I doubt Sunflower seeds (or any other seeds) will have been approved by regulators by then, but hopefully at least submitted for consideration. PM and DM will have been approved, but highly unlikely to have a meaningful impact on 2025, but certainly a foundation for future years. Of course hopefully the USA market will begin to show a meaningful contribution to bottom line by the end of 2025 too. I agree the insecticide opportunities are massive for Eden, but the jury is still out on what impact that is going to have on 2025 imo. Eden officially says there is lots of interest and my conversations with Sean back that up, but yet currently has no deal on the table. Are they haggling over detail or miles apart in terms of price and commercials? Time will tell, but what I have been unable to get from my conversations is what next after the commercials are agreed. How quickly to regulators and how quickly to market. They seem unwilling or unable to make comment on that, which makes me a little nervous as the timeline for that could be a nasty surprise. |
Posted at 10/11/2024 08:22 by supersonico Stone Fruits;"There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years" .................... Investingisatrickyga It does imply that this approval will lead to other regulators viewing this and actioning the same. I'm looking at Almonds in California! Investingisatrickyga California produces 80% of the world's Almonds and is 100% of US production. Californian Almond crop production is expected to be 21% higher in 2024 over 2023. Almonds are California's 3rd most valuable crop. I fully expect Sipcam to get that label extension. .................... Biofungicide Label Extension in Spain 24 June 2024 This newly expanded label makes Araw one of the most versatile and reliable solutions to prevent fungal diseases in many crops under organic and conventional agriculture. Thanks to this new authorisation, obtained through Sipcam's local regulatory team, all relevant horticultural crops in Spain can now be protected with Araw representing an excellent opportunity in several crops of growing importance, such as avocado, mango, and almond, which has become the third largest tree crop in Spain after olives and grapes. Spain boasts the largest cultivated area of almond trees in the world and ranks third in terms of overall production. Eden anticipates that this growth of the addressable market for Araw will contribute to revenue in 2025 and beyond. Further details of this expansion will be provided in due course as commercialisation commences. Sean Smith, Chief Executive Officer of Eden Research, commented: "Today's announcement is an excellent demonstration of our strategy to pursue growth opportunities through both new product introductions and with existing products by targeting new crop types and new disease targets. We are delighted to build on the success of our longstanding relationship with Sipcam. They have done an outstanding job of making the Iberian region an important and strong revenue-generating territory for the Company. This label extension represents a significant additional growth opportunity for us. It not only includes numerous new crops and diseases, but it also includes a number of high-value crops that are particularly disease prone." |
Posted at 10/11/2024 08:14 by supersonico 15 December 2022Eden Research Plc ("Eden" or "Company") Distribution Agreement for Mevalone in France Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable biopesticides and plastic-free formulation technology for use in the global crop protection, animal health and consumer products industries, announces that it has signed an agreement ("Agreement") with Corteva France ("Corteva") which allows Corteva to market, distribute and sell Eden's fungicide product, Mevalone®, in France on an exclusive basis. Mevalone is Eden's flagship, sustainable, foliar biofungicide, which is used to treat Botrytis cinerea on grapes and various other crops, a fungal disease commonly found in crops exposed to humid conditions. Eden also recently received authorisation for the use of Mevalone on pome fruits, including apples and pears, in France to help treat post-harvest diseases that arise during storage, thereby significantly reducing food waste. .................... There is significant future potential to expand the use of Mevalone for the treatment of powdery and downy mildews and field trials for these applications on grapes are currently underway, with the potential to expand further to include crops such as berries and stone fruits. All expanded uses of Mevalone are, as always, subject to regulatory approval, which is anticipated in the coming years. .................... France is widely recognised for its agricultural output, which is well-known for its high quality. France's vineyards are the country's biggest consumers of plant protection products, which include fungicides, insecticides, and herbicides. Although viticulture represents just 3% of France's agricultural land, the sector consumes 20% of the country's fungicides. It also represents 15% of French agricultural produce in value terms; an exciting landscape in which Eden's biopesticides will play an expanded role. The Agreement with Corteva will be implemented immediately with commercial progress expected over the course of the next year as Eden transitions from its current distribution arrangements. Sean Smith, CEO of Eden Research plc, commented: "Expanding our partnership with agriscience powerhouse Corteva reflects the further execution and acceleration of Eden's commercial strategy. Eden has a strong existing partnership with Corteva with our ongoing collaboration around the development of seed treatments, and this Agreement marks the expansion of our relationship with the focus of this Agreement being to increase Eden's commercial presence in the all-important French grape and pome fruits markets. "Corteva's vast presence in France will enable Eden to capitalise on the significant commercial opportunities that exist within this expansive market and has strong potential to increase Eden's product sales revenue. Coupled with our recently received EPA approval in the US, this Agreement highlights the global demand for sustainable biopesticides and the strides Eden is making to broaden its global footprint and accelerate commercial growth." Sylvain Bedel, Managing Director of Corteva France said: "We are pleased to be expanding our working relationship with Eden by supplying to farmers Eden's innovative bio-solutions in the French market. There is a strong demand for more sustainable growing practices in France and farmers are paying increasing attention to consumer demand for such practices. Eden's unique technology helps provide a much-needed solution." |
Posted at 07/11/2024 22:12 by supersonico Second Ecovelex 2024 Approval announced ~6 weeks earlier than 2023.Full EU🧑&# .................... Eden Research and Corteva Agriscience Announce Ecovelex?2023 Approval in Italy Cremona, Italy and Abingdon, UK - December 18, 2023 - Corteva Agriscience and Eden Research are pleased to announce that Ecovelex? 2023 has been granted, according to Reg. EU/1107/2009, a temporary approval in Italy for use as a bird repellent seed treatment in corn for the 2024 growing season. Eden is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products. ............. Ecovelex Approval in Italy 07 November 2024 Eden Research plc ("Eden") is pleased to announce that Ecovelex™ 2024 has been granted, according to Reg. EU/1107/2009, approval in Italy for use as a bird repellent seed treatment in corn for the 2025 growing season. Eden is a leader in sustainable biopesticide and biocontrol products and technologies. |
Posted at 23/10/2024 13:41 by supersonico Conspiracy theory?? hahaNot surprised as it was a conference call link from 2023..I expect they all have an expiry date. '''''''''''''''''''' Commentary extract came from this post; supersonico - 13 May 2023 - 07:09:20 - 14068 of 18967 Eden Research - EDEN Yes, Trials for seed treatment (coatings) which is due for commercialization for 2024 growing season and then I think he's referring to SustainE 'within' Pioneer seeds. Interesting Sam Eathington commentary @1hr29m in the Corteva Innovation Web cast in referring to EU approvals sounds very confident in Corteva's 'regulatory capacity to get things approved around the world is quite beneficial there'. Also Eden have Mike Carroll on hand as our trusty Corteva link man to provide network benefits. Also Smith's reference @6.17 to the 80 plus field trials for the insecticide treatment which could again be Corteva @Pioneer or Whale2. If it is Corteva then I'm even more inclined to think we'll see some sort of strategic partnership announcement. The Corteva French commentary regarding the 10x of addressable market that Smith refers to in the investor presentation event is making Corteva a very important partner and they may just want a bit of the ££benefit from the scale they bring to the party in what Sam Eathington calls 'unique value sharing collaborations'. “Our R&D program is also delivering innovation by moving faster on new opportunities such as biologicals to help farmers meet changing food production demands and the potential for double cropping systems that provide another cash crop option for farmers,â€ʏ Of course with Whale2 onboard as well Eden may have enough leverage to be considered 'external innovation' to them both. What anyone who is paying attention is certainly seeing is a step change in Eden's growth prospects and the PR noise that goes along with that. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
